Small Business Translator: MedTech and Digital Health Technologies
ID: 359156Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Small Business Translator: MedTech and Digital Health Technologies" aimed at encouraging small business concerns (SBCs) to engage in translational activities and clinical studies for the development of innovative health technologies. This cooperative agreement program seeks to advance technologies that prevent, monitor, diagnose, and treat various disorders, with a focus on devices such as wearables, digital health tools, and imaging-based biomarkers, among others. Participants will receive funding for activities conducted in their laboratories and may also collaborate with consultants for specialized support, with key deadlines including an estimated synopsis close date of October 20, 2025, and an estimated award date of July 1, 2026. For further inquiries, interested applicants can contact Nicholas Langhals, PhD, at Blueprint-MedTech@nih.gov or by phone at 301-435-0090.

    Point(s) of Contact
    Nicholas Langhals, PhD National Institute of Neurological Disorders and Stroke (NINDS)
    (301) 435-0090
    Blueprint-MedTech@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Forecast for Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) for the Blueprint MedTech Translator program, aimed at supporting small businesses in the development of innovative medical devices for the nervous and neuromuscular systems. This cooperative agreement will provide non-dilutive funding and additional resources to facilitate the translation of groundbreaking technologies from early-stage development to clinical studies, ultimately accelerating patient access to effective medical devices. Interested applicants should note that while applications are not currently being solicited, they are encouraged to begin forming collaborations and developing projects in anticipation of the NOFO, with an estimated synopsis posting date of July 21, 2025, and a closing date of October 20, 2025. For further inquiries, potential applicants can contact Nicholas Langhals, PhD, at Blueprint-MedTech@nih.gov or by phone at 301-435-0090.
    Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)" aimed at supporting innovative research in the development of therapeutic and diagnostic devices for disorders affecting the nervous or neuromuscular systems. This cooperative agreement program encourages investigators to conduct translational activities and clinical feasibility studies, with a focus on advancing medical device technology through collaboration with NIH resources for design, testing, and regulatory support. The initiative is particularly significant as it seeks to accelerate the clinical introduction of medical technologies, ultimately improving patient outcomes while adhering to best practices in research and development. Interested applicants, including various eligible institutions and organizations, must submit their proposals by January 28, 2028, and can find more information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Opportunities for Collaborative Research at the NIH Clinical Center
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Opportunities for Collaborative Research at the NIH Clinical Center," aimed at supporting collaborative translational research projects that enhance the application of basic biological discoveries to clinical settings. This program encourages partnerships between NIH intramural investigators and extramural researchers to accelerate patient-centric translational research, focusing on understanding disease processes and developing new therapeutic interventions, diagnostics, or prevention strategies. Interested small businesses can apply for this cooperative agreement, with no cost-sharing requirement, and should note that the estimated synopsis post date is September 1, 2025, with a closing date of December 12, 2025. For further inquiries, applicants can contact Dr. David J. Eckstein at 301-496-4121 or via email at ClinicalCtrPartner@mail.nih.gov.
    PRIMED-AI: Translating Models to Clinic (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "PRIMED-AI: Translating Models to Clinic," aimed at developing innovative AI-based tools that integrate clinical imaging with multimodal health data to enhance personalized medicine for patients with chronic conditions. This initiative, part of the Precision Medicine with Artificial Intelligence program, will utilize a biphasic mechanism focusing initially on rigorous AI model building through the analysis of large datasets, with successful projects advancing to evaluate the clinical utility of AI-driven Clinical Decision Support tools. The estimated total program funding is $10.2 million, with applications expected to be solicited after the synopsis posting on July 1, 2025, and a closing date anticipated on November 1, 2025. Interested applicants can contact Dr. Sahana N. Kukke at ODPRIMED-AI@od.nih.gov or by phone at 301-402-3756 for further information.
    NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Not Allowed) aimed at encouraging United States small business concerns (SBCs) to engage in research and development projects aligned with NIH's mission. Eligible applicants, defined as SBCs by the Small Business Administration, are invited to prepare for future submissions of Phase I, Phase II, Fast-Track, and Phase IIB grant applications, although applications are not currently being solicited. This funding opportunity is significant for fostering innovative health-related research and collaboration among small businesses and NIH institutes. Interested parties can reach out to the NIH SEED Office of Extramural Research at SEEDinfo@nih.gov or by phone at 301-827-8595 for further information, with the estimated synopsis posting date set for October 1, 2025, and a projected award date of June 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement: Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at soliciting applications for research focused on developing biomedical technologies that address health disparities. This initiative seeks to support projects that create effective, affordable, and socially acceptable technologies to improve healthcare access and outcomes for underserved populations. The estimated total program funding for this opportunity is $1,200,000, with an expected two awards to be made, and the application process is anticipated to open in late 2025. Interested applicants can reach out to Nichole Daringer at nichole.daringer@nih.gov or call 301-451-4774 for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint MedTech: Prototype Developer (U18 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity announcement for the Blueprint MedTech: Prototype Developer program, aimed at supporting the development of human-grade medical device prototypes. This initiative will utilize the U18 activity code and is designed to assist projects in completing product definition and development, including needs assessment, product design, prototype development, and bench testing, ultimately preparing for first-in-human testing through subsequent FOAs. The program is significant for advancing medical technology and innovation in healthcare, with no cost-sharing or matching requirements. Interested applicants can reach out to Michael Wolfson, Ph.D., at 301-451-6987 or via email at Blueprint-MedTech@nih.gov for further information. The estimated synopsis post date was July 15, 2021, with applications expected to be due in Fall 2021, and the anticipated award date is June 1, 2022.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Translational Neural Devices (R61/R33 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This initiative encourages investigators to engage in translational activities and small clinical studies, focusing on the implementation of clinical prototype devices, non-clinical safety and efficacy testing, and obtaining necessary regulatory approvals for clinical trials. The program emphasizes a milestone-driven approach, requiring collaboration with NIH staff throughout the project, and aims to address health disparities in neurological health. Interested applicants, including various educational and community organizations, must submit their proposals by January 28, 2027, and can find additional information and application guidelines at NIH Grants.
    NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NeuroNEXT Small Business Innovation in Clinical Trials," aimed at encouraging small businesses to conduct exploratory clinical trials of investigational agents related to neurological disorders. This initiative seeks applications for Phase II Small Business Innovation Research (SBIR) projects, with a budget of up to $3 million over five years, focusing on trials that align with the strategic plan of the National Institute of Neurological Disorders and Stroke (NINDS). The program is designed to foster public-private partnerships to enhance the development and commercialization of innovative therapies, ultimately improving clinical outcomes in neuroscience research. Interested applicants must adhere to a Community Engagement and Research Inclusion (CERI) plan, with the first application deadline set for January 5, 2025, and additional deadlines throughout 2026 and 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.